CAR-T

Gilead’s Kite Pharma gets FDA nod for second CAR-T cell therapy
MedCity News
Sat, 07/25/20 - 02:29 pm
Gilead Sciences
CAR-T
KTE-X19
Tecartus
FDA
Kite Pharma
Death in Cellectis off-the-shelf CAR-T trial triggers FDA hold
Fierce Biotech
Tue, 07/7/20 - 10:39 am
Cellectis
CAR-T
UCARCS1A
Multiple Myeloma
patient deaths
FDA
Bayer-backed Century buys Empirica to create brain cancer CAR-Ts
Fierce Biotech
Tue, 06/23/20 - 11:01 am
Century Therapeutics
Empirica
cell therapies
brain cancer
glioblastoma
CAR-T
Sana Biotechnology raises more than $700M for cell, gene therapy efforts
MedCity News
Tue, 06/23/20 - 10:42 am
Sana Biotechnology
Juno Therapeutics
CAR-T
Poseida Therapeutics guns again for IPO
Fierce Biotech
Mon, 06/22/20 - 10:32 am
Poseida Therapeutics
CAR-T
IPOs
Gilead sees better days ahead for CAR-T therapy Yescarta with Amsterdam manufacturing hub online
Fierce Pharma
Mon, 06/15/20 - 11:08 pm
Gilead Sciences
CAR-T
Yescarta
Amsterdam
drug manufacturing
ASCO 2020 round-up: Virtual conference still delivers the drama ASCO 2020 round-up: Virtual conference still delivers the drama
Pharmaforum
Fri, 06/5/20 - 10:30 am
ASCO 2020
Amgen
AstraZeneca
Bristol-Myers Squibb
cancer
CAR-T
COVID-19
Keytruda
Kyprolis
Tagrisso
ASCO: Allogene reports 63% response rate in early trial of off-the-shelf CAR-T in lymphoma
Fierce Biotech
Fri, 05/29/20 - 10:57 am
Allogene
ASCO 2020
CAR-T
ALLO-501
ALLO-647
lymphoma
CMS proposes 1.6% inpatient increase and new CAR-T cell therapy payment
Healthcare Finance News
Tue, 05/12/20 - 10:13 pm
CMS
Medicare
CAR-T
cell therapy
Gilead, Kite pen natural killer pact with little-known Australian cell therapy player
Fierce Biotech
Wed, 04/22/20 - 11:04 am
Gilead Sciences
Kite Pharma
oNKo-innate
CAR-T
natural killer cell therapies
Calling Gilead's CAR-T infringement 'willful,' judge enhances BMS' award to $1.2B
Fierce Pharma
Fri, 04/10/20 - 10:23 am
Gilead Sciences
CAR-T
patents
Bristol-Myers Squibb
J&J inks Fate deal to move into allogeneic CAR therapies
Fierce Biotech
Fri, 04/3/20 - 12:29 pm
JNJ
Fate Therapeutics
CAR NK
CAR-T
cell therapies
drug development
Motion denied: Gilead still on the hook for $1.5B in damages over CAR-T patent dispute with Bristol Myers Squibb
Endpoints
Wed, 04/1/20 - 09:33 am
Gilead Sciences
CAR-T
Bristol-Meyers Squibb
Juno Therapeutics
patents
Daiichi Sankyo submits application for CAR T therapy axicabtagene ciloleucel to treat patients with certain relapsed/refractory B-cell lymphomas in Japan
Pharmaceutical Business Review
Tue, 03/31/20 - 11:05 am
Daiichi Sankyo
Japan
CAR-T
axicabtagene ciloleucel
relapsed or refractory diffuse large B-cell lymphoma
Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for Celgene/bluebird CAR-T
Endpoints
Tue, 03/31/20 - 10:47 am
Bristol-Meyers Squibb
CAR-T
Celgene
ide-cel
Bluebird Bio
liso-cel
ozanimod
AbbVie-backed Carisma's 'CAR-M' tech shrinks tumors in mouse models of ovarian cancer
Fierce Biotech
Tue, 03/24/20 - 10:43 am
ovarian cancer
Carisma Therapeutics
CAR-M
CAR-T
J&J's favorite CAR-T developer, currently owned by a Chinese CRO, is laying the groundwork for US IPO
Endpoints
Tue, 03/10/20 - 11:05 am
CAR-T
IPOs
GenScript
CROs
China
JNJ
Scorpion Venom Could Improve Immuno-Oncology Therapies in Brain Cancer
BioSpace
Thu, 03/5/20 - 10:49 am
brain cancer
drug development
CAR-T
City of Hope
scorpion venom
Morphosys’ off-the-shelf rival to CAR-T approaches finish line with a speedy review
Endpoints
Mon, 03/2/20 - 09:37 am
MorphoSys
Gilead Sciences
Novartis
CAR-T
tafasitamab
DLBCL
Cellectis boosts its coffers in revised off-the-shelf CAR-T deal with Servier
Endpoints
Wed, 02/19/20 - 09:56 am
CAR-T
Cellectis
Servier
UCART19

Pages